Results 191 to 200 of about 38,769 (305)

Zinc Potentiates the Renoprotective Effects of SGLT2 Inhibitors in Experimental Diabetes Mellitus in Rats. [PDF]

Life (Basel)
Anton IC, Solcan C, Mititelu Tartau L, Amalinei C, Poroch M, Poroch V, Buca BR, Tartau CG, Tartau CG, Pelin AM, Botnariu GE.   +10 more
europepmc   +1 more source

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim   +7 more
wiley   +1 more source

Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis. [PDF]

Front Med (Lausanne)
Hu Q, Jin H, Li X, Hu L.
europepmc   +1 more source

Diagnosis and management of equine metabolic syndrome

Equine Veterinary Education, EarlyView.
Summary Equine metabolic syndrome (EMS) is a prevalent endocrine disorder that increases the risk of hyperinsulinaemia‐associated laminitis (HAL), the most common and clinically significant form of laminitis. The central pathological feature of EMS is insulin dysregulation (ID), which encompasses basal or postprandial hyperinsulinaemia and tissue ...
F. R. Bertin
wiley   +1 more source

Impact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study. [PDF]

J Acquir Immune Defic Syndr
Haidar L, Crane HM, Nance RM, Doupe MB, Leong C, Bamford L, Burkholder G, Cachay E, Christopoulos K, Commanday A, Aboulatta L, Delaney JAC, Drumright LN, Fahey CA, Heath S, Kalayjian R, Kitahata MM, Kyle RP, Mayer KH, Moore RD, Pettit AC, Napravnik S, Ruderman SA, Saag MS, Willig AL, Whitney BM, Eltonsy S.   +26 more
europepmc   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Internal Medicine Journal, EarlyView.
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy, Kitty St Pierre, Emily Major, Stephen I. Alexander, Brydee Cashmore, Helen Coolican, Vanessa Cullen, Jessica Dawson, Kelly Lambert, Vincent W. Lee, Amali Mallawaarachi, Gopala Rangan, Judy Savige, Santosh Varughese, David J. Tunnicliffe, Andrew J. Mallett, on behalf of the CARI Guidelines Steering Committee, Emily See, Leanne Brown, Jonathan Craig, Jeffrey Ha, Rathika Krishnasamy, Casey Light, Emmy O'Neill, Thu Nguyen, Hannah Smith, Andrea Viecelli   +26 more
wiley   +1 more source

Letter to the Editor: re-evaluating comparative efficacy of SGLT2 inhibitors in heart failure. [PDF]

Ann Med Surg (Lond)
Lambert M.
europepmc   +1 more source

Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve

Internal Medicine Journal, EarlyView.
Abstract Background Sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) improve symptoms, reduce hospitalisations and increase survival in patients with heart failure with reduced ejection fraction (HFrEF). This study evaluated SGLT2i prescribing compliance in hospitalised patients with HFrEF at an Australian tertiary hospital.
Salim Memon, Kanishaa Subhaharan, Tasnuba Ashan, Rogges Anandarajah, Nuwan Jasenthu Kankanamage   +4 more
wiley   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors. [PDF]

Eur J Clin Pharmacol
Falsetti L, Tarquinio N, Mucci L, Santini S, Guerrieri E, Giovenali L, Pierdomenico G, Zaccone V, Viticchi G, Moroncini G.   +9 more
europepmc   +1 more source